
    
      This is an open-label Phase 1 study of a single oral tablet of TR-701 FA 200 mg to compare
      the TR-700 PK profile in elderly subjects (age 65 years and older, with at least 5 subjects
      75 years old or older) and younger control subjects (age 18 to 45 years).
    
  